 Connection
John Mitchell to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications John Mitchell has written about Carcinoma, Non-Small-Cell Lung.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.471 |
|
|
|
-
Kaza AK, Mitchell JD. Preoperative pulmonary evaluation of the thoracic surgical patient. Thorac Surg Clin. 2005 May; 15(2):297-304.
Score: 0.132
-
Stuart CM, Mott NM, Bronsert MR, Randhawa SK, David EA, Mitchell JD, Meguid RA. The Association Between Sociodemographic Factors and Delays to Minimally Invasive Surgery for Stage IA-IIIA Non-small Cell Lung Cancer. Ann Thorac Surg. 2025 May; 119(5):1082-1091.
Score: 0.128
-
Altorki N, Wang X, Damman B, Jones DR, Wigle D, Port J, Conti M, Ashrafi AS, Liberman M, Landreneau R, Yasufuku K, Yang S, Mitchell JD, Keenan R, Bauer T, Miller D, Kozono D, Mentlick J, Vokes E, Stinchcombe TE. Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2024 Sep 01; 10(9):1179-1186.
Score: 0.126
-
Stinchcombe TE, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Altorki N. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Apr 01; 42(10):1110-1113.
Score: 0.120
-
Stuart CM, Dyas AR, Bronsert MR, Velopulos CG, Randhawa SK, David EA, Mitchell JD, Meguid RA. The Effect of Social Vulnerability on Initial Stage and Treatment for Non-Small Cell Lung Cancer. Lung Cancer. 2024 02; 188:107452.
Score: 0.120
-
Dyas AR, Bronsert MR, Stuart CM, Thomas MB, Schulick RD, Franco SR, Gleisner A, Randhawa SK, David EA, Mitchell JD, Meguid RA. Analyzing the impact of the Coronavirus disease 2019 pandemic on initial oncologic presentation and treatment of non-small cell lung cancer in the United States. J Thorac Cardiovasc Surg. 2024 Aug; 168(2):378-390.e7.
Score: 0.119
-
Altorki N, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Stinchcombe TE. Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance). J Thorac Cardiovasc Surg. 2024 01; 167(1):338-347.e1.
Score: 0.116
-
Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes E. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023 02 09; 388(6):489-498.
Score: 0.113
-
Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 03; 165(3):828-839.e5.
Score: 0.110
-
Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018 12; 6(12):915-924.
Score: 0.084
-
Bruno TC, Ebner PJ, Moore BL, Squalls OG, Waugh KA, Eruslanov EB, Singhal S, Mitchell JD, Franklin WA, Merrick DT, McCarter MD, Palmer BE, Kern JA, Slansky JE. Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. Cancer Immunol Res. 2017 10; 5(10):898-907.
Score: 0.077
-
Peled N, Hakim M, Bunn PA, Miller YE, Kennedy TC, Mattei J, Mitchell JD, Hirsch FR, Haick H. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol. 2012 Oct; 7(10):1528-33.
Score: 0.055
-
Yu JA, Li H, Meng X, Fullerton DA, Nemenoff RA, Mitchell JD, Weyant MJ. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1479-85.
Score: 0.055
-
Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol. 2010 Jul 01; 28(19):3131-7.
Score: 0.047
-
Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006 Mar 01; 12(5):1507-14.
Score: 0.035
-
Solomon B, Mitchell JD, Bunn PA. Adjuvant chemotherapy for resected non-small-cell lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1685-97; discussion 1698-700, 1705.
Score: 0.034
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|